CMPX (Compass Therapeutics) OCF Yield %: -12.63 (As of Jul. 09, 2026)


CMPX Compass Therapeutics Inc CMPX
23 GF Score
Price $2.34
! 2 Warning Signs
View Full Analysis

What is Compass Therapeutics OCF Yield %?

Compass Therapeutics CMPX +0.86% 23 OCF Yield % is -12.63 as of Jul. 09, 2026. GuruFocus rates CMPX with a GF Score™ of 23/100. The stock has 2 warning signs investors should review. Among 1,408 Biotechnology companies, Compass Therapeutics ranks worse than 60.01% on this metric.

OCF Yield % is calculated as Cash Flow from Operations divided by Market Capitalization. It is a financial solvency ratio that compares the operating cash flow a company is expected to earn against its market value.

As of today, Compass Therapeutics's Trailing 12-Month Cash Flow from Operations is $-53.20 Mil, and Market Cap is $421.41 Mil. Therefore, Compass Therapeutics's OCF Yield % for today is -12.63%.

The historical rank and industry rank for Compass Therapeutics's OCF Yield % or its related term are showing as below:

CMPX' s OCF Yield % Range Over the Past 10 Years
Min: -38.99   Med: -13.01   Max: -4.9
Current: -12.63


During the past 8 years, the highest OCF Yield % of Compass Therapeutics was -4.90%. The lowest was -38.99%. And the median was -13.01%.

CMPX's OCF Yield % is ranked worse than
60.01% of 1408 companies
in the Biotechnology industry
Industry Median: -7.975 vs CMPX: -12.63

Compass Therapeutics's OCF Margin % for the quarter that ended in Mar. 2026 was %.


Compass Therapeutics OCF Yield % Explanation

Similar to Earnings Yield %, OCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high operating cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.


Compass Therapeutics OCF Yield % Related Terms


Compass Therapeutics OCF Yield % Historical Data

* Premium members only.

The historical data trend for Compass Therapeutics's OCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Compass Therapeutics OCF Yield % Chart

Compass Therapeutics Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
OCF Yield %
Get a 7-Day Free Trial -6.15 -5.37 -20.39 -22.45 -5.13

Compass Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
OCF Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -20.11 -13.16 -6.98 -5.54 -7.25

CMPX vs XFOR, LRMR, PROK: OCF Yield % Comparison

For the Biotechnology subindustry, Compass Therapeutics's OCF Yield %, along with its competitors' market caps and OCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Compass Therapeutics OCF Yield % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Compass Therapeutics's OCF Yield % distribution charts can be found below:

* The bar in red indicates where Compass Therapeutics's OCF Yield % falls into.


CMPX
23GF Score
Compass Therapeutics Inc CMPX
OCF Yield % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Compass Therapeutics OCF Yield % Calculation

OCF Yield % is a financial solvency ratio that compares the operating cash flow a company is expected to earn against its market value.

Compass Therapeutics's OCF Yield % for the fiscal year that ended in Dec. 2025 is calculated as

OCF Yield %=Cash Flow from Operations / Market Cap
=-49.143 / 957.59988
=-5.13%

Compass Therapeutics's annualized OCF Yield % for the quarter that ended in Mar. 2026 is calculated as

OCF Yield %=Cash Flow from Operations * Annualized Factor / Market Cap
=-17.269 * 4 / 952.66552
=-7.25%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about OCF Yield % →
What does a OCF Yield % of -12.63 mean?
Compass Therapeutics (CMPX) has a OCF Yield % of -12.63 as of Jul. 09, 2026. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Compass Therapeutics and its competitors. According to the industry distribution chart, Compass Therapeutics ranks #845 out of 1408 companies in the Biotechnology industry, placing it in the top 60%.
Is Compass Therapeutics' OCF Yield % too high?
Compass Therapeutics' current OCF Yield % is -12.63. Based on the distribution chart, Compass Therapeutics ranks #845 out of 1408 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Compass Therapeutics has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does Compass Therapeutics' OCF Yield % compare to XFOR and LRMR?
According to the Biotechnology industry distribution chart, Compass Therapeutics ranks #845 out of 1408 companies for OCF Yield %. This places Compass Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Yield % for a Biotechnology company?
A good OCF Yield % depends on the Biotechnology industry context. However, OCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Yield % mean?
A high OCF Yield % can signal that a stock is expensive relative to its fundamentals. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Compass Therapeutics and its competitors. Compass Therapeutics's current OCF Yield % is -12.63. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Compass Therapeutics stock overvalued right now?
Compass Therapeutics (CMPX) has a current OCF Yield % of -12.63. The current OCF Yield % is -12.63. Compass Therapeutics' overall GF Score™ is 23/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Yield % calculated?
OCF Yield % is calculated from a company's financial statements. For Compass Therapeutics (CMPX), the current OCF Yield % is -12.63 as of Jul. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Compass Therapeutics Business Description

Address 80 Guest Street, Suite 601, Boston, MA, USA, 02135
Compass Therapeutics Inc is a clinical-stage oncology-focused biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to target the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-A, Bispecific, and CTX-8371.
23GF Score

Get the complete analysis for CMPX

OCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.34
Price